To include your compound in the COVID-19 Resource Center, submit it here.

Spectrum lifts on Phase II NSCLC data

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) soared $5.21 (36%) to $19.67 on Wednesday after reporting interim data from a Phase II study of poziotinib (HM781-36B) to treat non-small

Read the full 269 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE